epidemiolog
data
coronavirus
cov
human
bocaviru
hbov
set
allogen
hematopoiet
stem
cell
transplant
allohsct
scarc
conduct
prospect
longitudin
studi
respiratori
viral
infect
rvi
allohsct
recipi
respiratori
symptom
decemb
june
respiratori
viru
upper
andor
lower
respiratori
tract
urt
lrt
specimen
test
use
luminex
xtag
rvp
fast
assay
seventynin
consecut
allohsct
recipi
develop
total
virolog
document
rvi
episod
month
median
followup
rvi
day
rang
cov
hbov
detect
episod
recipi
develop
total
cov
rvi
episod
wherea
recipi
hbov
rvi
episod
fourteen
cov
rvi
episod
limit
urt
wherea
affect
lrt
copathogen
detect
cov
case
type
cov
domin
type
follow
cov
hospit
rate
wherea
mortal
patient
without
microbiolog
document
among
recipi
hbov
lrt
involv
one
die
respiratori
failur
case
hbov
detect
along
viral
copathogen
cov
rvi
common
allohsct
signific
proport
case
cov
progress
lrt
show
moder
sever
clinic
featur
contrast
hbov
rvi
rare
mostli
present
context
coinfect
import
amount
data
concern
frequent
communityacquir
respiratori
virus
carv
respiratori
syncyti
viru
rsv
human
parainfluenza
viru
hpiv
human
influenza
viru
human
metapneumoviru
hmpv
human
rhinoviru
set
allogen
hematopoiet
stem
cell
transplant
allohsct
carv
caus
upper
andor
lower
respiratori
tract
diseas
urtd
lrtd
allohsct
associ
high
morbid
mortal
recent
avail
sophist
diagnost
tool
base
revers
transcript
pcr
rtpcr
improv
diagnosi
carv
led
identif
new
emerg
respiratori
virus
coronavirus
cov
human
bocaviru
hbov
howev
littl
known
epidemiolog
preval
clinic
featur
cov
hbov
immunocompromis
patient
date
human
cov
identifi
name
sever
acut
respiratori
syndrom
cov
middl
east
respiratori
syndrom
cov
alphacoronavirus
betacoronavirus
known
contribut
commoncold
infect
human
circul
simultan
affect
peopl
without
underli
condit
case
report
detail
instanc
sever
covrel
pneumonia
immunocompromis
adult
pediatr
patient
treat
hematolog
malign
howev
largest
seri
biolog
blood
marrow
transplant
j
u
r
n
l
h
e
p
g
e
w
w
w
b
b
r
g
cov
analyz
allohsct
patient
publish
date
prospect
observ
studi
detect
cov
allohsct
recipi
estim
incid
day
stem
cell
infus
hbov
howev
origin
identifi
random
pcr
amplificationclon
techniqu
pool
respiratori
secret
hospit
children
respiratori
tract
infect
symptom
viru
affect
young
children
winter
season
howev
scarc
data
avail
concern
relationship
hbov
respiratori
diseas
immunocompromis
patient
preliminari
evid
case
report
describ
dissemin
hbov
infect
involv
respiratori
tract
blood
stool
sever
patient
sometim
associ
graftversushost
diseas
gvhd
prolong
fecal
viral
shed
studi
howev
report
littl
evid
link
viru
pulmonari
patholog
sever
respiratori
diseas
allohsct
lung
transplant
recipi
thu
conduct
prospect
epidemiolog
studi
respiratori
viral
infect
rvi
allohsct
recipi
develop
urtd
lrtd
symptom
allohsct
report
frequenc
clinic
featur
cov
hbov
urtd
lrtd
diagnos
rtpcr
seri
patient
singl
center
period
prospect
longitudin
studi
rvi
adult
year
allohsct
recipi
time
allograft
followup
transplant
unit
studi
purpos
late
implement
medic
informationeduc
recipi
caregiv
explain
detail
risk
rvi
context
immunosuppress
specif
inform
includ
descript
respiratori
symptom
report
soon
possibl
transplant
team
recommend
concern
infecti
prevent
control
measur
patient
healthcaregiv
telephon
number
oncal
hour
emerg
condit
also
provid
current
studi
cohort
compris
consecut
allohsct
recipi
virolog
document
rvi
diagnos
hospit
clinic
universitari
valencia
studi
period
recipi
respiratori
symptom
decemb
june
prospect
screen
carv
realtim
pcr
clinic
biolog
characterist
prospect
record
report
detail
elsewher
immunodefici
score
index
isi
variabl
record
first
clinic
evalu
previous
describ
detail
clinic
assess
also
perform
prospect
record
transplant
databas
time
respiratori
symptom
note
clinic
manifest
includ
rhinorrhea
cough
rale
wheez
short
breath
dyspnea
sinus
otiti
pharyng
tonsil
fever
temperatur
retrospect
analyz
epidemiolog
cov
hbov
detect
local
ethic
committe
approv
studi
subject
gave
written
inform
consent
particip
studi
urtd
defin
combin
upper
respiratori
symptom
rhinorrhea
sinus
otiti
pharyng
posit
identif
carv
pcr
test
absenc
lower
respiratori
tract
infect
symptom
andor
indic
pulmonari
infiltr
radiolog
result
chest
xray
comput
tomographi
scan
classifi
lrtd
possibl
confirm
previous
describ
possibl
lrtd
defin
detect
carv
nasopharyng
sputum
sampl
taken
patient
show
clinic
symptom
tracheiti
bronchiti
bronchiol
pneumonia
new
onset
cough
rale
wheez
coughrel
chest
pain
short
breath
dyspnea
hypoxia
new
detect
abnorm
pulmonari
function
conjunct
identif
new
pulmonari
infiltr
without
confirm
presenc
lower
respiratori
tract
confirm
lower
respiratori
tract
infect
defin
abovement
clinic
featur
accompani
isol
viru
tracheal
aspir
bronchoalveolar
lavag
bal
accord
fourth
european
confer
infect
leukaemia
recommend
defin
episod
urtd
lrtd
infecti
diseas
episod
consid
resolv
complet
remiss
respiratori
symptom
observ
episod
respiratori
tract
infecti
diseas
document
symptomfre
period
least
consecut
week
resolut
previou
episod
andor
isol
differ
viru
conjunct
onset
new
respiratori
symptom
respiratori
coinfect
defin
identif
addit
microbiolog
agent
includ
bacteri
fungal
specimen
andor
carv
sampl
either
upper
lower
respiratori
tract
recipi
develop
sign
symptom
urtd
andor
lrtd
underw
detail
virolog
bacteri
fungal
evalu
bronchoscopi
perform
detail
microbiolog
evalu
includ
respiratori
virus
bacteri
fungal
acidfast
bacilli
cultur
aspergillu
galactomannan
assay
detect
cytomegaloviru
perform
patient
urtd
symptom
underw
nasopharyng
aspir
nasopharyng
swab
induc
sputum
test
wherea
bal
perform
patient
lrtd
whenev
possibl
clinic
sampl
test
rtpcr
use
luminex
xtag
rvp
fast
assay
luminex
austin
tx
describ
detail
elsewher
briefli
specimen
receiv
laboratori
within
minut
collect
conserv
process
within
hour
receipt
nucleic
acid
extract
perform
use
qiagen
viral
extract
kit
robot
qiagen
valencia
ca
luminex
xtag
rvp
fast
assay
detect
adenovirus
hbov
cov
influenza
influenza
influenza
virus
nonsubtypifi
influenza
b
viru
hmpv
b
hpiv
rsv
ab
enterovirusrhinoviru
evrh
primari
object
describ
epidemiolog
cov
hbov
rvi
among
circul
carv
allohsct
set
secondari
endpoint
describ
clinic
characterist
outcom
patient
suffer
urtd
andor
ltrd
caus
virus
epidemiolog
clinic
rvi
characterist
compar
use
chisquar
test
categor
variabl
pair
student
ttest
continu
variabl
statist
signific
set
p
relev
standard
deviat
shown
allohsct
recipi
screen
upper
andor
lower
respiratori
tract
symptom
develop
least
episod
virolog
document
rvi
studi
period
clinic
biolog
characterist
subject
shown
tabl
note
seri
compris
highrisk
cohort
profound
immunosuppress
statu
recipi
includ
allograft
altern
donor
unrel
donor
haploident
famili
donor
least
antigen
mismatch
donor
hlaa
b
c
dr
allel
determin
highresolut
genotyp
addit
number
recipi
acut
chronic
gvhd
also
high
repres
allohsct
recipi
respect
although
frequenc
hospit
directli
attribut
rvi
high
overal
mortal
rel
low
entir
cohort
persontim
observ
cohort
personyear
studi
overal
identifi
least
carv
screen
episod
recipi
microbiolog
document
rvi
identifi
rsv
episod
hpiv
evrh
hiv
hmpv
adenovirus
cov
hbov
coinfect
virus
document
rvi
episod
shown
figur
carv
rvi
episod
occur
octob
june
autumn
winter
spring
summer
evrh
cov
hpiv
still
circul
diagnos
rvi
episod
first
month
shown
figur
cov
hbov
predomin
winter
month
decemb
march
episod
sporad
case
april
novemb
moreov
observ
increas
frequenc
cov
hbov
rvi
episod
studi
period
detect
cov
hbov
episod
carv
episod
respect
wherea
diagnos
cov
hbov
rvi
episod
carv
episod
respect
clinic
biolog
characterist
cov
rvi
detail
tabl
overal
recipi
suffer
least
cov
rvi
episod
fifteen
patient
develop
episod
wherea
cov
rvi
episod
among
recipi
episod
median
time
elaps
first
second
episod
day
rang
type
cov
detect
first
second
episod
differ
recipi
cov
type
type
anoth
third
figur
show
distribut
covtyp
rvi
frequent
cov
type
follow
type
tabl
show
clinic
biolog
characterist
rvi
accord
cov
type
type
appar
clinic
intens
reflect
higher
occurr
fever
copathogen
hospit
rate
lrtd
creactiv
protein
time
rvi
evalu
copathogen
detect
cov
rvi
episod
tabl
note
case
proven
cov
lrtd
also
bacteri
fungal
coinfect
detect
bal
case
stenotrophomona
maltophilia
mycobacterium
tuberculosi
respect
pneumocysti
jirovecci
detect
pcr
coinfect
limit
recipi
allograft
altern
donor
versu
p
howev
observ
statist
differ
term
clinic
present
lower
respiratori
tract
infect
admiss
rate
monoand
coinfect
overal
recipi
cov
rvi
die
one
patient
die
respiratori
distress
syndrom
day
identif
cov
type
nasal
swab
microbiolog
document
site
includ
blood
urin
stool
cultur
isi
score
high
point
possibl
covrel
lrtd
radiolog
document
day
stem
cell
infus
thu
three
patient
episod
cov
anoth
episod
hbov
respiratori
infect
variabl
assess
time
rvi
diagnosi
possibl
lrtd
case
show
radiolog
pattern
suggest
viral
etiolog
microbiolog
agent
isol
site
case
cov
hbov
upper
respiratori
tract
consid
higher
mgl
mortal
directli
attribut
cov
rvi
two
recipi
die
month
cov
rvi
episod
diseas
progress
obliteran
bronchiol
respect
clinic
biolog
characterist
hbov
rvi
detail
tabl
overal
recipi
suffer
episod
hbov
rvi
interestingli
hbov
detect
case
also
test
posit
coinfect
virus
case
evrh
hpmv
given
high
frequenc
coinfect
case
hbov
detect
seri
question
put
pathogen
effect
hbov
respiratori
tract
patient
refer
respiratori
detect
instead
respiratori
infect
mention
hbov
detect
hbov
patient
possibl
lrtd
like
caus
evrh
three
recipi
hbov
detect
respiratori
secret
requir
hospit
admiss
possibl
lrtd
none
patient
hbov
respiratori
detect
die
studi
period
prospect
longitudin
rvi
survey
studi
provid
insight
epidemiolog
type
cov
clinic
featur
cov
rvi
characterist
hbov
respiratori
detect
allohsct
set
cov
andor
hbov
detect
allohsct
recipi
develop
least
episod
virolog
document
urtd
lrtd
period
month
togeth
carv
repres
document
rvi
episod
observ
period
observ
signific
proport
cov
rvi
requir
hospit
progress
lrt
contrast
hbov
detect
rare
commonli
associ
copathogen
seri
frequenc
cov
rank
fifth
evrh
hpiv
rsv
influenza
virus
respect
recent
publish
prospect
data
indic
hrhv
cov
second
commonli
detect
viru
allohsct
recipi
day
stem
cell
infus
data
set
suggest
cov
rvi
common
allohsct
set
includ
screen
test
respiratori
symptom
present
carv
rvi
diagnos
expand
scenario
line
previou
report
also
found
cov
rvi
exhibit
winter
season
even
though
seri
still
mani
case
may
interestingli
although
number
allohsct
remain
stabl
studi
period
allohsct
per
year
notic
increas
number
frequenc
cov
detect
carv
gener
year
studi
conduct
diagnos
total
number
cov
rvi
repres
rvi
year
wherea
first
half
number
frequenc
increas
cov
rvi
episod
total
rvi
episod
respect
observ
merit
attent
first
like
learn
curv
effici
identifi
recipi
respiratori
symptom
ask
appropri
screen
test
entir
hematolog
team
includ
fellow
involv
project
becam
progress
awar
import
monitor
viral
infect
allohsct
recipi
especi
outofhour
period
night
weekend
fact
could
partli
explain
signific
differ
rate
document
carv
rvi
n
number
rvi
per
month
compar
rvi
episod
per
month
n
first
month
n
p
respect
although
fact
could
regard
limit
like
occur
sever
site
novel
strategiesprotocol
implement
second
although
studi
period
extend
complet
respiratori
viru
season
rule
possibl
season
chang
commonli
seen
preval
carv
may
influenc
differ
cov
rvi
rate
observ
first
half
final
exclud
possibl
peak
preval
cov
rvi
commun
anoth
import
observ
case
cov
detect
associ
copathogen
especi
virus
thu
support
prior
find
codetect
common
rais
interest
question
concern
role
copathogenesi
diseas
allohsct
recipi
high
frequenc
coinfect
seri
make
difficult
interpret
clinic
signific
cov
clinic
effect
attribut
presenc
alon
limit
number
case
viral
coinfect
report
medic
literatur
limit
knowledg
clinic
relev
coinfect
allohsct
set
thu
analysi
put
clinic
effect
cov
detect
copathogen
compar
rvi
caus
singl
viral
agent
would
use
line
futur
investig
although
clinic
signific
cov
poorli
understood
prospect
studi
review
suggest
may
occasion
caus
lrtd
allohsct
overal
progress
rate
seem
low
howev
data
indic
least
cov
rvi
progress
proven
lrtd
reach
possibl
lrtd
consid
remain
unknown
presenc
copathogen
favor
cov
progress
lrtd
addit
cov
rvi
led
hospit
admiss
fever
dyspnea
clinic
instabl
case
suggest
cov
rvi
could
moder
sever
allohsct
recipi
addit
support
care
common
requir
relat
studi
patient
repres
total
cov
case
possibl
lrtd
high
isi
die
respiratori
failur
soon
transplant
microbiolog
document
site
sampl
cov
type
nasal
swab
day
death
find
line
recent
retrospect
studi
presenc
cov
bal
sampl
immunocompromis
host
significantli
associ
high
rate
respiratori
support
mortal
similar
establish
respiratori
pathogen
includ
rsv
influenza
viru
hpiv
regard
cov
type
contrast
milano
et
al
other
observ
common
circul
cov
recipi
type
follow
subtyp
order
agre
epidemiolog
data
infant
adult
sever
countri
contin
may
valuabl
vaccin
develop
purpos
author
suggest
order
might
consequ
gener
crossreact
antibodi
infect
may
protect
infect
respect
howev
protect
relationship
may
reciproc
interestingli
common
cov
type
show
clinic
ntens
featur
reflect
higher
occurr
fever
copathogen
hospit
rate
lrtd
creactiv
protein
fact
might
relat
patient
immunogen
epidemiolog
intrigu
merit
studi
contrast
cov
rvi
clinic
impact
hbov
infect
allohsct
ambigu
similar
mani
report
observ
signific
hbov
copathogenesi
found
posit
hbov
sampl
test
posit
copathogen
difficult
interpret
given
scarc
clinic
evid
pathogenesi
hbov
alon
allohsct
recipi
recent
casecontrol
studi
shown
similar
rate
hbov
genom
dna
detect
symptomat
asymptomat
children
suggest
detect
impli
necessarili
pathogen
respiratori
tract
studi
found
hbov
capsid
mrna
detect
could
differenti
acut
infect
prolong
shed
still
seri
hbov
detect
rare
phenomenon
repres
carv
find
agre
preliminari
allohsct
data
cumul
incid
hbov
detect
first
day
final
acknowledg
studi
limit
includ
rel
small
cohort
size
decis
classifi
lrtd
possibl
proven
may
led
us
overestim
true
lrtd
rate
howev
prospect
natur
studi
homogen
viral
diagnost
tool
use
part
studi
strength
summari
data
confirm
cov
riv
common
allohsct
progress
lrtd
case
lead
hospit
requir
support
care
contrast
hbov
quit
rare
commonli
detect
conjunct
viral
copathogen
howev
fact
current
limit
us
draw
firm
conclus
concern
clinic
signific
hbov
detect
pathogen
rvi
allohsct
